

Targeted treatment of pruritus: a look into the future

H.L. Tey* and G. Yosipovitch*†‡

Department of *Dermatology, †Neurobiology & Anatomy, and ‡Regenerative Medicine, Wake Forest University School of Medicine, Winston-Salem, NC 27157-1071, U.S.A.

Summary

Correspondence

Gil Yosipovitch.

E-mail: gyosipov@wfubmc.edu

Accepted for publication

2 January 2011

Funding sources

G.Y. is funded by NIH Ro-11R01AR055902-01A1.

Conflicts of interest

G.Y. is on the advisory board of GlaxoSmithKline and served as consultant for Regeneron, Johnson & Johnson and Unilever. H.L.T. has no conflicts of interest.

DOI 10.1111/j.1365-2133.2011.10217.x

Recent advances in pruritus research have elucidated mediators and neuronal pathways involved in itch transmission, and this fast emerging knowledge may possibly be translated into new therapies in the near future. In the skin and peripheral nerves, potential mediator and receptor therapeutic targets include the H4 histamine receptor, protease-activated receptor 2, serine proteases, cathepsin S, peripheral mu- and kappa-opioid receptors, interleukin-31, transient receptor potential vanilloid 1 and 3, fatty acid amide hydrolase, nerve growth factor and its receptor, acetylcholine, and the Mas-related G protein-coupled receptors. In the spinal cord, gastrin-related peptide and its receptor, as well as substance P and its receptor neurokinin receptor-1 serve as potential therapeutic targets. In the brain, reduction of itch perception and modulation of emotions may possibly be achieved through drugs acting on the anterior cingulate cortex. Clinically, management of pruritus should be instituted early and should address the skin pathology, peripheral neuropathy, central sensitization, and the cognito-affective aspects of the disease.

Pruritus is a common symptom and a source of significant morbidity.¹ However, research in itch, unlike pain, has not received much interest until the current decade and management of pruritic conditions has been hampered by our inadequate understanding of the pathophysiology of itch. Recent advances have elucidated the mediators and neuronal pathways involved in itch transmission (Fig. 1), and it may be that this fast emerging knowledge will be translated into new therapeutics in the near future. In addition to reviewing promising new agents, this article highlights important recent findings in the pathogenesis of itch and explores how the mediators and receptors involved can serve as potential targets for the development of novel antipruritic drugs in various diseases (Tables 1 and 2).

Antihistamines

Histamine has been the prototypic pruritogen for decades² but robust evidence for its role and the efficacy of histamine H1 receptor antagonists is limited to only a few diseases (namely urticaria, mastocytosis, allergic drug reactions and insect bite reactions). The role of histamine in most forms of chronic pruritus (defined as more than 6 weeks by the International Forum for the Study of Itch)³ is minimal and H1 antihistamines are frequently ineffective in these conditions. The recent discovery of H3 and H4 histamine receptors and their involve-

ment in pruritus and inflammation⁴⁻⁷ has, however, rekindled interest in histamine. In particular, the H4 receptor, first cloned in 2000,⁸ has been found to be involved in allergic inflammation and the functioning of mast cells, eosinophils, monocytes, dendritic cells and T cells.⁸⁻¹¹

In mice, H4 histamine receptor agonists have been shown to induce pruritus that was independent of mast cells or other haematopoietic cells; this suggests that the H4 receptor-mediated itch results from a direct action on peripheral nerves.⁶ The H4 receptor antagonist JNJ-777120 (Johnson & Johnson Pharmaceutical Research & Development, New Brunswick, NJ, U.S.A.) has been demonstrated to be efficacious in models of pruritus, asthma and allergic rhinitis.¹²⁻¹⁴ Antagonism of the H4 receptor was also able to inhibit substance P-induced pruritus,¹⁵ which was resistant to H1 receptor antagonists.^{15,16} The effect of H4 receptor antagonism on both pruritus and Th2 cell-mediated inflammation highlights its therapeutic potential in atopic dermatitis (AD).¹⁷ Clinical studies are currently ongoing and this novel form of antipruritic treatment is expected to be available in the near future.¹⁸

Protease pathway

A distinct itch transmission pathway mediated by the pruritogen cowhage has been elucidated in recent years.¹⁹ Cowhage is a tropical plant and the spicules on its pods contain a




Fig 1. Current understanding of the pathological mechanisms of itch and the potential targets for itch therapeutics in the periphery, spinal cord and brain. Histamine-induced itch is transmitted via histamine-sensitive and mechanically insensitive C-fibres and protease-induced itch is transmitted via PAR-2 and mechanically positive C-fibres. Free nerve endings reach the stratum granulosum. Neurogenic inflammation is mediated by the axonal reflex, releasing neuropeptides (substance P in particular), which cause vasodilation and further inflammatory changes. PAR, protease-activated receptor; Mech., mechanical; Hist., histamine; GRP, gastrin-releasing peptide; GRPR, GRP receptor; Mrgpr, Mas-related G protein-coupled receptor; TRPV, transient receptor potential vanilloid; NKR-1, neurokinin receptor-1

cysteine protease, known as mucunain, which binds to protease-activated receptor (PAR)-2 and PAR-4²⁰ to stimulate cutaneous mechanical-sensitive C-fibres.²¹ The secondary neurones of these peripheral nerves were also found to be distinct from the neuronal pathway transmitting histamine-induced itch in primates,²² although findings of a study in mice suggested a functional overlap between these two pathways in the spinal cord.²³ The protease-PAR-2 pathway appears to be a suitable model for the study of itch in AD. Cowhage-induced itch, similar to that of AD, does not have accompanying axonal reflex flare, is associated with burning and/or pricking sensations,²⁴ and can be induced mechanically.¹⁹ PAR-2 receptors, which cowhage binds to, were found to be increased in AD lesions.²⁵ We have also recently found that cowhage induces a far more intense sensation compared with histamine and that the protease pathway is likely to be the main determinant of itch perception when both histamine and protease pathways are activated together.²⁶ The protease pathway therefore plays an important role in itch transmission in AD and probably also in other chronic pruritic conditions.

One approach in the management of pruritus is to target the specific components in the protease pathway, which consists of PAR-2 and endogenous proteases. These endogenous proteases includes serine proteases such as mast cell trypsinase^{26,27} and kallikreins,²⁸ and cysteine proteases such as cathepsin S.²⁹ In addition to pruritus, serine proteases signalling through PAR-2 have been shown to play a regulatory role in epidermal barrier function³⁰ and skin inflammation.²⁸ Serine proteases and PAR-2 may therefore be therapeutic targets in AD, which consists of all these three features, and in other conditions such as pruritus of the elderly and ichthyosis.

Nafamostat mesilate and camostat mesilate are synthesized serine protease inhibitors that inactivate trypsinase and kallikrein. Nafamostat mesilate, which has been used as an anticoagulant, has also been shown to inhibit mast cell activation and the production of inflammatory cytokines.^{31,32} The successful treatment of two patients with refractory chronic urticaria with nafamostat mesilate and camostat mesilate has recently been reported.³³ Nafamostat mesilate was also found to give effective inhibition of scratching in mice, mainly via its action on trypsinase.^{26,27}

Another group of drugs that target the protease pathway is the tetracyclines. Tetracycline and its derivatives, doxycycline and minocycline, were found to reduce PAR-2-mediated production of interleukin (IL)-8 in keratinocytes.³⁴ Tetracyclines can potentially be useful in inflammatory diseases which are pruritic, such as subsets of acne vulgaris and bullous pemphigoid, by reducing both inflammation and pruritus through their antagonistic effect on PAR-2. PAR-2 antibodies [such as SAM-11 (Santa Cruz Biotechnology, Santa Cruz, CA, U.S.A.) and P2pal-21³⁵] and antagonists [such as FSLRY (Peptides International, Louisville, KY, U.S.A.) and ENMD-1068³⁶] have been used in mice to inhibit itch induced by trypsinase and itch occurring in AD and chronic dry skin.^{26,27,37} Another potential therapeutic target is cysteine protease, and an inhibitor targeting cathepsin S (E-64³⁸) has been used in laboratory studies to inhibit itch signalling.^{20,29}

Opioid system

It is well known that the opioid system has a role in itch processing in the central nervous system. There is growing

Table 1 Emerging and potential targeted antipruritic agents

Site and mechanism of action	Promising drugs/research molecules
Skin and peripheral nerves	
H4 histamine receptor antagonism	JNJ-777120
Protease-activated receptor-2 inhibition	Antibodies SAM-11 P2pal-21 ³⁵
	Antagonists Tetracyclines FSLRY ENMD-1068 ³⁶
Serine proteases inhibition	Nafamostat mesilate Camostat mesilate E-64 ³⁸
Cathepsin S inhibition	Anti-IL-31 antibody
Interleukin-31 (IL-31) inhibition	Peripherally active antagonists Methylnaltrexone Alvimopan
Mu-opioid receptor antagonism	Peripherally active agonists Asimadoline SA14867 ICI 204,448
Kappa-opioid receptor agonism	Transdermal 8% capsaicin (Qutenza) Tacrolimus ointment
Transient receptor potential vanilloid 1 activation	–
Transient receptor potential vanilloid 3 inhibition	Fatty acid amide hydrolase inhibitors URB597 (KDS-4103) (centrally active) URB937 (peripherally restricted)
Cannabinoid receptor activation	Tanezumab K252a AG879
Nerve growth factor inhibition	Botulinum toxin (subcutaneous and topical)
Tropomyosin-related kinase A inhibition	–
Acetylcholine inhibition	–
Mas-related G protein-coupled receptor antagonism	–
Lysophosphatidic acid and autotaxin inhibition	–
Periphery and central nervous system	
Mu-opioid receptor antagonism	Topical antagonist Naltrexone 1% cream
Kappa-opioid receptor agonism	Systemic agonists Bremazocine GR 89696 ⁴⁸
	Topical agonist Butorphanol (liposomal formulation)
Spinal cord	
Substance P inhibition/Neurokinin receptor-1 (NKR-1) antagonism	NKR-1 antagonists Aprepitant Fosaprepitant Casopitant Vestipitant Orvepitant Ezlopitant Lanepitant Dapitant L-733,060
Gastrin-related peptide (GRP) inhibition/GRP receptor antagonism	–
Cerebrum	
Modulation of itch perception	Esmirtazapine Serotonin–noradrenaline reuptake inhibitors Venlafaxine/desvenlafaxine Duloxetine Milnacipran/levomilnacipran Bicifadine NKR-1 antagonists Vestipitant L-733,060

Table 2 Potential new therapies in various pruritic diseases

Pruritic disease and target	Potential new therapies
Atopic dermatitis	
Histaminergic pathway	H4 histamine receptor antagonists
Protease pathway	Serine protease inhibitors Cysteine protease inhibitors
	PAR-2 antagonists and antibodies
Opioid system	Topical and systemic, peripheral and centrally-acting mu-receptor antagonists and kappa-receptor agonists
IL-31	Anti-IL-31 antibody
Cannabinoids	FAAH inhibitors (centrally and peripherally acting agents)
Neurotrophins	Anti-NGF antibodies TrkA inhibitors
Cerebral processes	Esmirtazapine
Pruritus of chronic liver disease	
Opioid system	Kappa-receptor agonists (centrally and peripherally acting agents) Peripherally acting mu-receptor antagonists
Pruritogens in blood	LPA and autotaxin inhibitors (in cholestatic liver disease)
Malignancy associated itch (especially cutaneous T-cell lymphoma)	
Substance P–NKR-1	NKR-1 antagonists
Cerebral processes	Esmirtazapine
Prurigo nodularis and lichen simplex chronicus	
Opioid system	Topical naltrexone Topical butorphanol Kappa-receptor agonists (centrally and peripherally acting agents)
	8% Capsaicin
TRPV1	Anti-IL-31 antibody
IL-31	Anti-NGF antibodies
Neurotrophins	TrkA inhibitors
Neuropathic itch	
TRPV1	8% Capsaicin
Neurotrophins	Anti-NGF antibodies TrkA inhibitors
Cerebral processes	SNRIs
Pruritus of the elderly	
Protease pathway	Serine protease inhibitors Cysteine protease inhibitors PAR-2 antagonists and antibodies
Chronic itch associated with mood disorders	
Cerebral processes	Esmirtazapine SNRIs
Substance P–NKR-1	NKR-1 antagonists
Morphine-induced itch	
Opioid system	Kappa-receptor agonists (centrally and peripherally acting agents) Peripherally acting mu-receptor antagonists
Chloroquine-induced itch	
Opioid system	Kappa-receptor agonists
Mrgprs	Mrgpr inhibitor
GRP–GRPR	GRP inhibitor GRPR antagonist

PAR, protease-activated receptor; IL, interleukin; FAAH, fatty acid amide hydrolase; NGF, nerve growth factor; Trk, tropomyosin-related kinase A; LPA, lysophosphatidic acid; NKR-1, neurokinin receptor-1; TRPV1, transient receptor potential vanilloid 1; SNRIs, serotonin–noradrenaline reuptake inhibitors; Mrgprs, Mas-related G protein-coupled receptors; GRP, gastrin-releasing peptide; GRPR, GRP receptor.

evidence, however, that opioid receptors and endogenous opioid agonists are also functional in the skin, and they have been found on peripheral nerve fibres, keratinocytes, melanocytes, hair follicles and immune cells.³⁹ It is believed that an

excess of mu-opioid receptor activity in comparison with kappa-opioid receptor activity results in pruritus,⁴⁰ and stimulation of the kappa-opioid receptor was found to inhibit mu-receptor effects both centrally and peripherally.^{41,42}

Mu-opioid receptor antagonists, such as naloxone, naltrexone and nalmefene, have been shown in controlled clinical trials to be effective in treating pruritus associated with cholestasis, atopic dermatitis and chronic urticaria.^{43–45} Nalfurafine, a kappa-opioid receptor agonist, has been shown to reduce uraemic itch significantly,⁴⁶ and was approved for use for this purpose in Japan in 2009. Its efficacy in the pruritus of chronic liver disease has also been investigated in a phase II trial,⁴⁷ but the results are currently unavailable. Two other kappa-opioid receptor agonists, bremazocine and GR 89696,^{48,49} have been shown in monkey models to inhibit itch induced by intrathecal morphine. Butorphanol is both a kappa-receptor agonist and a mu-receptor antagonist; the epidural form was found to be effective in relieving pruritus associated with epidural morphine⁵⁰ and the intranasal form has been reported to be effective in patients with severe and intractable pruritus secondary to systemic and inflammatory skin diseases.⁵¹

Nausea and analgesia withdrawal are significant problems associated with opioid antagonists, and central nervous system depression and addiction are important side-effects with opioid agonists. Peripherally acting opioid receptor agonists and antagonists, which do not cross the blood–brain barrier, are devoid of such central effects and provide an alternative to circumvent these problems.

Subcutaneous methylnaltrexone is a peripherally active mu-opioid receptor antagonist approved in the U.S.A. for use in patients under palliative care who do not respond sufficiently to laxative therapy. The drug has also been approved for use by Health Canada and the European Medicines Agency. In a double-blind randomized controlled trial involving 10 healthy volunteers, oral methylnaltrexone at a dose of 19.2 mg kg⁻¹ significantly improved itch induced by intravenous morphine.⁵² Methylnaltrexone has also been used by anaesthesiologists for short-term management of pruritus in patients receiving intraspinal and epidural analgesia.⁵³ These results support the role of peripheral opioid receptors in mediating itch, but more studies are required to evaluate the efficacy of methylnaltrexone in pruritic conditions. Alvimopan is an orally administered peripherally acting mu-opioid receptor antagonist that has been approved in the U.S.A. for acceleration of gut function after bowel resection and primary anastomosis. Its efficacy as an antipruritic agent remains to be explored.

Preliminary data on peripherally acting kappa-opioid receptor agonists suggest that they may be useful in the treatment of itch. ICI 204,448 (Tocris Bioscience, Bristol, U.K.) has previously been shown to prevent chloroquine-induced itch in mice.⁵⁴ Asimadoline (EMD-61753), which is being developed for the treatment of irritable bowel syndrome,⁵⁵ has been reported to inhibit itch induced by compound 48/80 (which degranulates mast cells to release histamine) and a kappa-receptor antagonist.⁵⁶ SA14867 (Santen Pharmaceutical Co., Osaka, Japan) has been shown to inhibit itch induced by substance P and 5-hydroperoxyeicosatetraenoic acid in mice and to attenuate morphine-induced scratching in monkeys.⁵⁷

Topical preparations of opioid receptor agonist/antagonist, which would be useful in localized pruritic conditions, have been developed but are currently not commercially available. Naltrexone cream 1% has been used in patients with AD in an open study in which more than 70% of the 18 subjects experienced significant reduction in pruritus.⁵⁸ Subsequently, a placebo-controlled, crossover trial involving 40 patients with AD demonstrated that the cream was effective in reducing pruritus.⁵⁸ Lim *et al.*⁵⁹ formulated a topical liposomal butorphanol preparation and showed that the formulation is able to release a consistent amount of butorphanol into the systemic circulation over 24 h. This formulation, however, has not been tested in humans. Further trials involving the abovementioned topical agents will be required to demonstrate their clinical utility.

Interleukin-31

IL-31 is a cytokine that has been found to play an important role in pruritus.⁶⁰ Overexpression of IL-31 in lymphocytes in mice induced scratching and dermatitis,⁶¹ and higher levels of IL-31 have been found in the lesions of patients with AD and prurigo nodularis.⁶² A common IL-31 haplotype was found to be significantly associated with the nonatopic type of eczema (defined as the absence of specific IgE against common allergens), and this suggests that altered regulation of IL-31 gene expression is a risk factor for development of the disease.⁶³ A genetic mutation in the IL-31 receptor has also been recently implicated in the pathogenesis of familial primary cutaneous amyloidosis, a form of localized pruritic disease.^{64,65}

IL-31 is produced predominantly by Th2 lymphocytes,⁶¹ which are the main inflammatory cells in acute AD. Th1 lymphocytes, the predominant component of the inflammatory infiltrate in chronic AD, produce lesser amounts of IL-31.⁶¹ IL-31 receptors were found to have a much higher expression in the dorsal root ganglia compared with other tissues⁶² and IL-31 may exert its pruritogenic effect by directly binding to its receptors on cutaneous nerve fibres. Anti-IL-31 antibody has been demonstrated to reduce scratching during the onset of skin manifestations in a murine AD model,⁶⁶ and this result further supports the role of IL-31 as an important mediator of pruritus. Anti-IL-31 antibody may well serve as a new therapeutic approach in AD and other pruritic inflammatory skin diseases.

Vanilloids

Vanilloids are endogenous and exogenous agents that possess the ability to activate transient receptor potential vanilloid (TRPV) ion channels either directly or indirectly. The best known member is TRPV1, a nonselective cation channel expressed on both sensory neurones and non-neuronal cells (such as epidermal and hair follicular keratinocytes, mast cells, dendritic cells and endothelial cells).^{67–69} Activation of TRPV1 results in excitation and subsequent desensitization of C-fibres

through depletion of neuropeptides, a mechanism which has been utilized to alleviate pain and itch.^{70,71} TRPV1 was also found to be required in histamine- and serotonin-induced itch,⁷² and has been shown to mediate histamine-induced itch via activation of phospholipase A2 and 12-lipoxygenase.⁷³ Endogenous vanilloids consist of a heterogeneous group of mediators that include histamine, prostaglandins, bradykinin, eicosanoids, adenosine triphosphate and various neurotrophins.^{74–76}

Topical capsaicin, the active compound in chilli pepper, is an exogenous vanilloid. It has been shown to be useful in localized, chronic pruritic diseases, particularly those of neuropathic origin, such as postherpetic itch, brachioradial pruritus and notalgia paraesthetica.⁷⁷ It has also been used in pruritus associated with haemodialysis,⁷⁸ psoriasis⁷⁹ and aquagenic pruritus.⁸⁰ Capsaicin is available over the counter in concentrations of 0.025–0.1%, and the main problem with its use is the initial burning sensation which usually lasts several days. Patients can be advised to apply a topical anaesthetic, such as lignocaine or eutectic mixture of local anaesthetic (EMLA), before application of capsaicin in the first 2 weeks of treatment in order to reduce the discomfort. The topical anaesthetic, in addition, serves as an antipruritic treatment in itself. Pretreatment with an anaesthetic agent has been shown to give effective reduction of burning sensation and attenuate heat hyperalgesia during capsaicin treatment.⁸¹ A new high-potency transdermal formulation containing 8% capsaicin (Qutenza; NeurogesX, San Mateo, CA, U.S.A.; formerly NGX4010) has recently been approved in Europe and the U.S.A. for the treatment of postherpetic neuralgia. It was shown to be superior to a low-concentration formulation in the treatment of various types of neuropathic pain⁸² and a single 30- or 60-min application may provide up to 3 months of localized pain relief with minimal adverse effects. Although there are no data on its efficacy in neuropathic itch, this formulation is likely to be effective in these conditions and can be helpful in more resistant cases.

Tacrolimus is a calcineurin inhibitor that may inhibit pruritus through its effects on TRPV1. In addition to its anti-inflammatory action, tacrolimus has been reported to have direct antipruritic effects in AD and other diseases.^{83–85} It was found to induce the release of substance P from neurones, probably by favouring phosphorylation of TRPV1 and depleting phosphatidylinositol 4,5-bisphosphate, which in turn results in inactivation of calcium channels and desensitization of neurones.⁸⁶ Unlike capsaicin, it does not bind to TRPV1 directly.

TRPV3 channel is another member of the TRPV family, and has a role in thermosensation⁸⁷ and hair growth.⁸⁸ A study showed that TRPV3 transgenic mice with a Gly573Ser gain-of-function mutation developed allergic dermatitis and spontaneous scratching (which was unrelated to the dermatitis).⁸⁹ Like TRPV1, TRPV3 channels were found to be similarly expressed on keratinocytes and peripheral nerves. Modulation of these channels may potentially inhibit pruritus both at the epidermis (by inhibiting the production of itch mediators by

keratinocytes) and in the peripheral nerves.⁹⁰ In addition, certain agents such as camphor may act on both TRPV1 and TRPV3,⁹¹ and this creates the opportunity for using a single agent to target multiple receptors at multiple points in the itch signalling pathway.

Cannabinoids

The efficacy of cannabinoids in pruritus has been demonstrated in a few studies. Pretreatment with topical cannabinoid receptor agonists has been found to give significant reduction of histamine-induced itch and vasodilatation in healthy volunteers.^{92,93} In mice, cannabinoid receptor antagonists, such as rimonabant, have been shown to elicit a dose-dependent increase in scratching behaviour.⁹⁴

In a large industry-sponsored trial, a cream containing N-palmitoylethanolamine (PEA) was found significantly to reduce pruritus and improve disease severity in AD.⁹⁵ PEA was found to exhibit little affinity for cannabinoid receptors, but may act by enhancing the effect of anandamide, an endocannabinoid, through inhibition of the enzyme fatty acid amide hydrolase (FAAH).⁹⁶ Anandamide was found to reduce the activity of TRPV1 in primary sensory neurones, probably by reduction of protein kinase A-mediated phosphorylation of TRPV1.⁹⁷ The role of anandamide in itch has also been demonstrated in an acute allergic murine model in which suppression of neuronal FAAH [using FAAH inhibitor URB597 (KDS-4103) (Cayman Chemical, Ann Arbor, MI, U.S.A.)] reduced scratching response.⁹⁸ Direct-acting cannabinoid agonists also exert an antipruritic effect; however, unlike FAAH inhibitors, they have prominent central side-effects such as motor suppression, dependence and psychomimesis.^{98,99} In contrast to the centrally active URB597, a peripherally restricted FAAH inhibitor has also been developed recently. This inhibitor is known as URB937 and was shown to be effective in inhibiting pain in mice.¹⁰⁰ Research has been ongoing to examine drugs that prevent the catabolism of endogenous cannabinoids, and enzymes such as FAAH serve as targets for the development of new therapies for itch.^{98,99}

Neurotrophins

Neurotrophins are neuropeptides that regulate the growth and function of nerve cells. The prototypic neurotrophin is nerve growth factor (NGF), whose main sources are keratinocytes and mast cells.¹⁰¹ NGF has been shown to result in proliferation of nerve fibres¹⁰² and upregulation of neuropeptides such as substance P.¹⁰³ In AD lesions, higher levels of NGF have been found in keratinocytes in the epidermal basal and spinous layers, and increased density of NGF receptors, known as tropomyosin-related kinase A (TrkA), have been noted in the epidermis and upper dermis.¹⁰⁴ The level of NGF in the stratum corneum also correlated with the severity of itching and eruptions in AD.¹⁰⁵ Increased NGF and TrkA immunoreactivities have been detected in prurigo nodularis¹⁰⁶ and pruritic psoriatic lesions,¹⁰⁷ and higher local NGF concentrations

and increased fibre density have also been found in the pruritic lesions of contact dermatitis.¹⁰⁸

Anti-NGF strategies have been tested in the murine AD model. Anti-NGF antibodies were shown to give significant inhibition of the development and proliferation of AD lesions and to prevent proliferation of epidermal nerves.¹⁰⁹ TrkA inhibitors [K252a (Calbiochem, La Jolla, CA, U.S.A.) and AG879 (Alomone Labs, Jerusalem, Israel)] were also demonstrated to give significant improvement of established dermatitis and scratching behaviour, together with decreasing nerve fibre density in the epidermis.¹¹⁰ Of note, anti-NGF antibodies have been used to treat pain in patients,^{111–113} and tanezumab is a monoclonal antibody¹¹⁴ that has been investigated for the treatment of osteoarthritis and diabetic polyneuropathy in clinical trials.^{115,116} Anti-NGF strategies therefore provide another possible avenue for the management of chronic pruritus.

Other members of the neurotrophin family include neurotrophins 3, 4 and 5 and brain-derived neurotrophic factor (BDNF). Neurotrophin 4 was found to be increased in the prurigo lesions of patients with AD,¹¹⁷ and serum levels of BDNF correlated with the degree of nocturnal scratching, disease severity and quality of life in patients with AD.¹¹⁸ More studies will be required to clarify the roles of neurotrophin 4 and BDNF in pruritus and AD.

Acetylcholine

Acetylcholine is the main neurotransmitter in the autonomic nervous system, and may have a role in mediating pruritus. Elevated expression of acetylcholine has been found in the skin of patients with AD.¹¹⁹ Intradermal injection of acetylcholine induced pain but itch was produced when the injection was performed in lesional AD skin.^{120–122} This phenomenon, however, may also be explained by the central sensitization to itch that occurs in chronic AD.

Botulinum toxin inhibits the release of acetylcholine from presynaptic nerve terminals. It has been shown to reduce neurogenic inflammation (inflammation secondary to the release of neuropeptides from afferent neurones) induced by histamine, capsaicin and transcutaneous electrical stimulation.^{123–126} The usefulness of subcutaneous botulinum toxin in localized pruritus has been reported in cases of notalgia paraesthetica, lichen simplex chronicus and neuropathic itch;^{127–129} however, botulinum toxin has also been reported to be inefficacious for neuropathic itch in a case series.¹³⁰ The role of acetylcholine in pruritus and the benefits of targeting its action in therapeutics remain to be evaluated.

Toll-like receptor 7

In a recent study in mice, functional toll-like receptor 7 (TLR7) was found to be expressed in C-fibre sensory neurones and was important in mediating itch induced by nonhistaminergic pruritogens.¹³¹ Although TLR7 appears to be functionally conserved across mice and human species, studies are required to determine its role in pruritus in humans. The effectiveness

of antagonizing TRL7 to inhibit itch at the cutaneous level awaits evaluation.

Gastrin-releasing peptide and its receptor

The recent discovery of a specific group of interneurons in the dorsal horn of the spinal cord of mice provides evidence for a specific itch-transmitting central pathway that is distinct from pain signalling.^{132,133} The presence of such a pathway has long been a topic of debate. Gastrin-releasing peptide (GRP), a peptide initially discovered to play several roles in the regulation of gastrointestinal physiology, binds to GRP receptor (GRPR), a G protein-coupled receptor. In the study by Sun and Chen,¹³² GRP was found to be specifically expressed in a small subset of peptidergic neurones in the dorsal root ganglia and expression of GRPR was found to be restricted to lamina I of the dorsal horn of the spinal cord. Mice with mutant GRPR and mice with a GRPR antagonist injected into their spinal cerebrospinal fluid demonstrated significantly less scratching behaviour when compound 48/80, a PAR-2 agonist, and chloroquine were applied. The GRPR-mutant mice, however, demonstrated normal response to pain stimuli. Provided that a similar mechanism of itch transmission is present in humans, GRP and GRPR may be central targets that can be used to inhibit itch induced by different pruritogens.

Mas-related G protein-coupled receptors

A recent study in mice revealed that Mas-related G protein-coupled receptors (Mrgprs), a family of G protein-coupled receptors expressed exclusively in peripheral sensory neurones, function as receptors in chloroquine-induced itch.¹³⁴ Although Mrgprs do not seem to mediate histamine-induced itch, Mrgprs are activated by neuropeptides and it is possible that they may play a role in transmission of itch induced by other substances.¹³⁵ Interestingly, the peripheral sensory neurones expressing Mrgprs also expressed GRP. This gives further support to the presence of a group of peripheral C-fibres specifically transmitting itch. A molecular model for the transmission of itch induced by chloroquine and possibly other pruritogens can also be derived from this information: the pruritogen activates Mrgprs on peripheral nerves and stimulates release of GRP in the spinal cord, which in turn activates GRPR on spinal interneurons and subsequently activates the secondary itch neurones in the spinothalamic tract. Therefore, in addition to GRP and GRPR, Mrgprs provide molecular access to itch-selective neurones, and may serve as a potential target in itch therapeutics.

Substance P–neurokinin receptor

Substance P is an important neuropeptide mediating itch and neurogenic inflammation.^{136,137} It is a tachykinin that binds to neurokinin receptor (NKR)-1, NKR-2 and NKR-3,¹³⁸ but has the highest affinity for NKR-1. NKR-1 is expressed in the

central nervous system and the skin and NK1-expressing neurones in the superficial dorsal horn of the spinal cord were found to be involved in itch transmission in rats.¹³⁹

Aprepitant is a selective high-affinity NK1 antagonist which has been approved for the prevention of chemotherapy-induced emesis.¹⁴⁰ It has been reported to be effective in cases of Sézary syndrome, erythrodermic cutaneous T-cell lymphoma, metastatic sarcoma and breast carcinoma, erlotinib-induced itch, and chronic refractory pruritus from various causes.^{141–145} The drug has generally been well tolerated, and side-effects were mild. However, it is extremely expensive and its efficacy as an antipruritic agent requires verification in randomized controlled trials. Besides aprepitant, other NK1 antagonists are available, and some are under development. These drugs include fosaprepitant (intravenously administered prodrug of aprepitant), casopitant, vestipitant, orvepitant, ezlopitant, lanepitant, dapitant and L-733,060 (Merck, Sharp & Dohme, Whitehouse Station, NJ, U.S.A.). They possess antidepressant, anxiolytic and antiemetic properties and their utility in pruritic diseases remains to be explored.

Lysophosphatidic acid

A recent study showed that lysophosphatidic acid (LPA) functioned as a pruritogen in the sera of patients with cholestatic liver disease.¹⁴⁶ LPA is a phospholipid derivative synthesized by the enzyme autotaxin, and acts as a signalling molecule. In addition, the study found that the activity of autotaxin in patients' sera correlated with the presence and intensity of pruritus. LPA and autotaxin may therefore be potential targets in the treatment of cholestatic pruritus.

Cerebral processes

There is increasing evidence to support the phenomenon of central sensitization in chronic pruritus, a process analogous to central sensitization in chronic pain.^{147,148} This process is thought to occur in the spinal cord in both instances. The latter has been attributed to a defective descending pain-inhibitory system arising from various areas in the brainstem,¹⁴⁹ and the cortical connections of these regions are unknown. From the management point of view, treatment of pruritus should be instituted early to avoid development of central sensitization.

Little is known about the supraspinal processing of itch, and it is only in recent years that positron emission tomography and functional magnetic resonance imaging have been used to study the brains of healthy subjects and patients with AD. Induction of itch was found to activate various areas of the brain that are involved in sensory, motor and emotional functions, and these areas include the somatosensory areas I and II, supramarginal gyrus, inferior parietal lobe, anterior and posterior cingulate cortex, precuneus, and insula-claustrum complex. The areas of brain activation occurring in itch are similar to those of pain, except for the precuneus, which is involved in episodic memory retrieval

and may be associated with the affective components of itch.^{150,151} Among the areas activated in itch, the cingulate cortex appears to be an important region involved in the processing of pruritus. Compared with controls, the cingulate cortex was found to be significantly activated in patients with AD after histamine was administered, and the degree of activation correlated with disease severity.¹⁵⁰ The cingulate cortex was also found to be deactivated after scratching in healthy subjects.¹⁵²

In addition to somatosensory input, the perception and interpretation of pruritus are very much influenced by cognitive and affective processes. Antidepressants [selective serotonin reuptake inhibitors (SSRIs) and mirtazapine] and gamma-aminobutyric acid (GABA)-ergic drugs (namely gabapentin and pregabalin) have been found to be effective in treating itch; their mechanisms of actions are unknown but they may work by modulating itch perception. Serotonin and GABA were found to inhibit the cingulate cortex in mice,¹⁵³ and activity in the cingulate cortex may be a mechanism by which these serotonergic and GABA-ergic drugs exert their effects. The anterior cingulate cortex is known to be involved in emotional and cognitive functions (such as reward anticipation),¹⁵⁴ and with the recent findings of its role in pruritus, it appears to be an important target in the development of centrally active antipruritic agents.

Mirtazapine is a noradrenergic and specific serotonergic antidepressant that has been used to treat nocturnal itch¹⁵⁵ and malignancy-associated pruritus.^{156,157} Esmirtazapine (ORG-50,081), the (S)-(+)-enantiomer of mirtazapine, has a shorter half-life and is currently under development for the treatment of insomnia.^{158,159} Esmirtazapine would be a promising alternative for patients who benefit from mirtazapine but experience prolonged drowsiness following its use.

Serotonin–noradrenaline reuptake inhibitors (SNRIs) are a class of antidepressants which has been used in the treatment of anxiety disorders, chronic neuropathic pain and fibromyalgia.¹⁶⁰ Among them, venlafaxine, desvenlafaxine (the synthetic active metabolite of venlafaxine), duloxetine and bicifadine have been used to treat neuropathic pain, while duloxetine, milnacipran and levomilnacipran (levo-isomer of milnacipran) have been used to treat fibromyalgia. The efficacy of SNRIs in itch has not been assessed, but they may potentially be useful in neuropathic itch and chronic itch associated with depression and/or anxiety.

In addition to the SSRIs, mirtazapine, and the SNRIs, NK1 antagonists may also possess concurrent antidepressant, anxiolytic and antipruritic properties. Vestipitant is under clinical evaluation as an anxiolytic and a potential antidepressant,^{161,162} and L-733,060 has been shown in animal studies to have antidepressant^{163,164} and anxiolytic¹⁶⁵ effects. Aprepitant, however, was found in clinical trials to be ineffective for major depressive disorder¹⁶⁶ and plans to market it as an antidepressant have since been abandoned. The efficacy of NK1 antagonists in pruritus through antagonism of substance P activity and modulation of emotions awaits further elucidation.

Brain imaging has enabled identification of the various cerebral areas activated by itch. It should be noted, however, that the central mechanisms in different types of itch may differ. An example is seen in the use of gabapentin – it was shown to be efficacious in haemodialysis-associated pruritus^{167,168} but caused worsening of pruritus of cholestasis.¹⁶⁹ Treatment of pruritus should therefore be tailored to target the different pathological mechanisms in various diseases and also individualized according to the medical comorbidities and requirements of each patient.

From the clinical point of view, management of chronic pruritus must address not only the skin pathology, but also peripheral neuropathy (if present), central sensitization, and the cognito-affective aspects. Targeting the brain is also of particular relevance in skin diseases in which there are many different types of mediators and triggers involved in causing itch, such as AD. Attempts to inhibit multiple peripheral receptors and mediators with multiple agents will conceivably incur many unwanted side-effects, and mediating the cerebral processing of itch may be a more fruitful approach. Besides pharmacotherapy, psychotherapy can be used in management of the affective dimension, and the approaches include psychoanalysis, psychodynamic therapy, guided affective imagery¹⁷⁰ and hypnosis.^{171,172} Management of the cognitive processes includes providing education, support and cognitive-behavioural therapy.^{173,174}

Conclusion

With a better understanding of the pathological mechanisms of itch processing, targeting specific mediators and neuronal pathways offers a promising approach to more effective management of pruritus. In particular, the PAR-2 and H4 histamine receptor pathways, the opioid system, IL-31 and TRPV1 serve as targets for the development of novel antipruritic therapies. Clinically, management of pruritus should be instituted early and address the skin pathology, peripheral neuropathy, central sensitization and the cognito-affective aspects of the disease.

What's already known about this topic?

- Research interest in pruritus has spurred a tremendous increase in knowledge over the last few years.
- Management options for pruritus, however, are still limited and treatment is suboptimal.

What does this study add?

- Provides a review of the current knowledge and new discoveries regarding the pathogenesis of pruritus.
- Introduces promising drugs and identifies potential targets for the development of novel antipruritic therapies.

Acknowledgments

We thank Dr Alison Snodgrass for her invaluable editorial assistance.

References

- 1 Weisshaar E, Dalgard F. Epidemiology of itch: adding to the burden of skin morbidity. *Acta Derm Venereol* 2009; **89**:339–50.
- 2 Yosipovitch G. The pruritus receptor unit: a target for novel therapies. *J Invest Dermatol* 2007; **127**:1857–9.
- 3 Ständer S, Weisshaar E, Mettang T et al. Clinical classification of itch: a position paper of the International Forum for the Study of Itch. *Acta Derm Venereol* 2007; **87**:291–4.
- 4 Sugimoto Y, Iba Y, Nakamura Y et al. Pruritus-associated response mediated by cutaneous histamine H3 receptors. *Clin Exp Allergy* 2004; **34**:456–9.
- 5 Hossen MA, Sugimoto Y, Kayasuga R, Kamei C. Involvement of histamine H3 receptors in scratching behaviour in mast cell-deficient mice. *Br J Dermatol* 2003; **149**:17–22.
- 6 Bell JK, McQueen DS, Rees JL. Involvement of histamine H4 and H1 receptors in scratching induced by histamine receptor agonists in Balb C mice. *Br J Pharmacol* 2004; **142**:374–80.
- 7 Oda T, Morikawa N, Saito Y et al. Molecular cloning and characterization of a novel type of histamine receptor preferentially expressed in leukocytes. *J Biol Chem* 2000; **275**:36781–6.
- 8 Thurmond RL, Gelfand EW, Dunford PJ. The role of histamine H1 and H4 receptors in allergic inflammation: the search for new antihistamines. *Nat Rev Drug Discov* 2008; **7**:41–53.
- 9 Gutzmer R, Mommert S, Gschwandtner M et al. The histamine H4 receptor is functionally expressed on T(H)2 cells. *J Allergy Clin Immunol* 2009; **123**:619–25.
- 10 Dijkstra D, Leurs R, Chazot P et al. Histamine downregulates monocyte CCL2 production through the histamine H4 receptor. *J Allergy Clin Immunol* 2007; **120**:300–7.
- 11 Dijkstra D, Stark H, Chazot PL et al. Human inflammatory dendritic epidermal cells express a functional histamine H4 receptor. *J Invest Dermatol* 2008; **128**:1696–703.
- 12 Dunford PJ, Williams KN, Desai PJ et al. Histamine H4 receptor antagonists are superior to traditional antihistamines in the attenuation of experimental pruritus. *J Allergy Clin Immunol* 2007; **119**:176–83.
- 13 Bäumer W, Wendorff S, Gutzmer R et al. Histamine H4 receptors modulate dendritic cell migration through skin-immunomodulatory role of histamine. *Allergy* 2008; **63**:1387–94.
- 14 Rossbach K, Wendorff S, Sander K et al. Histamine H4 receptor antagonism reduces hapten-induced scratching behaviour but not inflammation. *Exp Dermatol* 2009; **18**:57–63.
- 15 Yamaura K, Oda M, Suwa E et al. Expression of histamine H4 receptor in human epidermal tissues and attenuation of experimental pruritus using H4 receptor antagonist. *J Toxicol Sci* 2009; **34**:427–31.
- 16 Togashi Y, Umeuchi H, Okano K et al. Antipruritic activity of the kappa-opioid receptor agonist, TRK-820. *Eur J Pharmacol* 2002; **435**:259–64.
- 17 Cowden JM, Zhang M, Dunford PJ, Thurmond RL. The histamine H4 receptor mediates inflammation and pruritus in Th2-dependent dermal inflammation. *J Invest Dermatol* 2010; **130**:1023–33.
- 18 Engelhardt H, Smits RA, Leurs R et al. A new generation of antihistamines: histamine H4 receptor antagonists on their way to the clinic. *Curr Opin Drug Discov Devel* 2009; **12**:628–43.

- 19 Namer B, Carr R, Johaneck LM et al. Separate peripheral pathways for pruritus in man. *J Neurophysiol* 2008; **100**:2062–9.
- 20 Reddy VB, Iuga AO, Shimada SG et al. Cowhage-evoked itch is mediated by a novel cysteine protease: a ligand of protease-activated receptors. *J Neurosci* 2008; **28**:4331–5.
- 21 Johaneck LM, Meyer RA, Friedman RM et al. A role for polymodal C-fiber afferents in nonhistaminergic itch. *J Neurosci* 2008; **28**:7659–69.
- 22 Davidson S, Zhang X, Yoon CH et al. The itch-producing agents histamine and cowhage activate separate populations of primate spinothalamic tract neurons. *J Neurosci* 2007; **27**:10007–14.
- 23 Akiyama T, Carstens MI, Carstens E. Excitation of mouse superficial dorsal horn neurons by histamine and/or PAR-2 agonist: potential role in itch. *J Neurophysiol* 2009; **102**:2176–83.
- 24 LaMotte RH, Shimada SG, Green BG, Zeltzman D. Pruritic and nociceptive sensations and dysesthesias from a spicule of cowhage. *J Neurophysiol* 2009; **101**:1430–43.
- 25 Steinhoff M, Neisius U, Ikoma A et al. Proteinase-activated receptor-2 mediates itch: a novel pathway for pruritus in human skin. *J Neurosci* 2003; **23**:6176–80.
- 26 Tsujii K, Andoh T, Ui H et al. Involvement of tryptase and proteinase-activated receptor-2 in spontaneous itch-associated response in mice with atopy-like dermatitis. *J Pharmacol Sci* 2009; **109**:388–95.
- 27 Ui H, Andoh T, Lee JB et al. Potent pruritogenic action of tryptase mediated by PAR-2 receptor and its involvement in anti-pruritic effect of nafamostat mesilate in mice. *Eur J Pharmacol* 2006; **530**:172–8.
- 28 Briot A, Deraison C, Lacroix M et al. Kallikrein 5 induces atopic dermatitis-like lesions through PAR2-mediated thymic stromal lymphopoietin expression in Netherton syndrome. *J Exp Med* 2009; **206**:1135–47.
- 29 Reddy VB, Shimada SG, Sikand P et al. Cathepsin S elicits itch and signals via protease-activated receptors. *J Invest Dermatol* 2010; **130**:1468–70.
- 30 Hachem J-P, Houben E, Crumrine D et al. Serine protease signaling of epidermal permeability barrier homeostasis. *J Invest Dermatol* 2006; **126**:2074–86.
- 31 Chen CL, Wang SD, Zeng ZY et al. Serine protease inhibitors nafamostat mesilate and gabexate mesilate attenuate allergen-induced airway inflammation and eosinophilia in a murine model of asthma. *J Allergy Clin Immunol* 2006; **118**:105–12.
- 32 Sendo T, Itoh Y, Goromaru T et al. A potent tryptase inhibitor nafamostat mesilate dramatically suppressed pulmonary dysfunction induced in rats by a radiographic contrast medium. *Br J Pharmacol* 2003; **138**:959–67.
- 33 Takahagi S, Shindo H, Watanabe M et al. Refractory chronic urticaria treated effectively with the protease inhibitors, nafamostat mesilate and camostat mesilate. *Acta Derm Venereol* 2010; **90**:425–6.
- 34 Ishikawa C, Tsuda T, Konishi H et al. Tetracyclines modulate protease-activated receptor 2-mediated proinflammatory reactions in epidermal keratinocytes. *Antimicrob Agents Chemother* 2009; **53**:1760–5.
- 35 Covic L, Gresser AL, Talavera J et al. Activation and inhibition of G protein-coupled receptors by cell-penetrating membrane-tethered peptides. *Proc Natl Acad Sci USA* 2002; **99**:643–8.
- 36 Kelso EB, Ferrell WR, Lockhart JC et al. Expression and proinflammatory role of proteinase-activated receptor 2 in rheumatoid synovium: ex vivo studies using a novel proteinase-activated receptor 2 antagonist. *Arthritis Rheum* 2007; **56**:765–71.
- 37 Akiyama T, Carstens MI, Carstens E. Enhanced scratching evoked by PAR-2 agonist and 5-HT but not histamine in a mouse model of chronic dry skin itch. *Pain* 2010; **151**:378–83.
- 38 Barrett AJ, Kembhavi AA, Brown MA et al. L-trans-Epoxy succinyl-leucylamide(4-guanidino)-butane (E-64) and its analogues as inhibitors of cysteine proteinases including cathepsins B, H and L. *Biochem J* 1982; **201**:189–98.
- 39 Bigliardi PL, Tobin DJ, Gaveriaux-Ruff C, Bigliardi-Qi M. Opioids and the skin – where do we stand? *Exp Dermatol* 2009; **18**:424–30.
- 40 Phan NQ, Bernhard JD, Luger TA, Ständer S. Antipruritic treatment with systemic μ -opioid receptor antagonists: a review. *J Am Acad Dermatol* 2010; **63**:680–8.
- 41 Pan ZZ. μ -Opposing actions of the kappa-opioid receptor. *Trends Pharmacol Sci* 1998; **19**:94–8.
- 42 Umeuchi H, Togashi Y, Honda T et al. Involvement of central μ -opioid system in the scratching behavior in mice, and the suppression of it by the activation of kappa-opioid system. *Eur J Pharmacol* 2003; **477**:29–35.
- 43 Mansour-Ghanaei F, Taheri A, Fraitan H et al. Effect of oral naltrexone on pruritus in cholestatic patients. *World J Gastroenterol* 2006; **12**:1125–8.
- 44 Monroe EW. Efficacy and safety of nalmefene in patients with severe pruritus caused by chronic urticaria and atopic dermatitis. *J Am Acad Dermatol* 1989; **21**:135–6.
- 45 Heyer G, Groene D, Martus P. Efficacy of naltrexone on acetylcholine-induced allokinesis in atopic eczema. *Exp Dermatol* 2002; **11**:448–55.
- 46 Wikstrom B, Gellert R, Ladefoged SD et al. Kappa-opioid system in uremic pruritus: multicenter, randomized, double-blind, placebo-controlled clinical studies. *J Am Soc Nephrol* 2005; **16**:3742–7.
- 47 Toray Industries, Inc. Phase II Study of TRK-820 Soft Capsules – Intractable Pruritus in Patients with Chronic Liver Disease. 2010. Available at: <http://clinicaltrials.gov/ct2/show/NCT00638495?term=nalfurafine&rank=2> (last accessed 5 February 2011).
- 48 Naylor A, Judd DB, Lloyd JE et al. A potent new class of kappa-receptor agonist: 4-substituted 1-(arylacetyl)-2-[(dialkylamino)methyl]piperazines. *J Med Chem* 1993; **36**:2075–83.
- 49 Ko MC, Husbands SM. Effects of atypical kappa-opioid receptor agonists on intrathecal morphine-induced itch and analgesia in primates. *J Pharmacol Exp Ther* 2009; **328**:193–200.
- 50 Kumagai H, Ebata T, Takamori K et al. Effect of a novel kappa-receptor agonist, nalfurafine hydrochloride, on severe itch in 337 haemodialysis patients: a phase III, randomized, double-blind, placebo-controlled study. *Nephrol Dial Transplant* 2010; **25**:1251–7.
- 51 Yokoyama Y, Yokoyama T, Nagao Y et al. Treatment of epidural morphine induced pruritus with butorphanol. *Masui* 2009; **58**:178–82.
- 52 Dawn AG, Yosipovitch G. Butorphanol for treatment of intractable pruritus. *J Am Acad Dermatol* 2006; **54**:527–31.
- 53 Yuan CS, Foss JF, O'Connor M et al. Efficacy of orally administered methyl naltrexone in decreasing subjective effects after intravenous morphine. *Drug Alcohol Depend* 1998; **52**:161–5.
- 54 Friedman JD, Dello Buono FA. Opioid antagonists in the treatment of opioid-induced constipation and pruritus. *Ann Pharmacother* 2001; **35**:85–91.
- 55 Tioga Pharmaceuticals. Asimadoline for the Treatment of Subjects with Irritable Bowel Syndrome. 2008. Available at: <http://www.clinicaltrials.gov/ct2/show/NCT00454688?term=asimadoline&rank=2> (last accessed 5 February 2011).
- 56 Cowan A, Inan S. Kappa opioid agonists as potential antipruritics. Presented at 40th Annual Meeting for the Society for Neuroscience, San Diego, U.S.A., 2010 (Abstract).
- 57 Tsukahara-Ohsumi Y, Tsuji F, Niwa M et al. SA14867, a newly synthesized kappa-opioid receptor agonist with antinociceptive and antipruritic effects. *Eur J Pharmacol* 2010; **647**:62–7.

- 58 Bigliardi PL, Stammer H, Jost G et al. Treatment of pruritus with topically applied opiate receptor antagonist. *J Am Acad Dermatol* 2007; **56**:979–88.
- 59 Lim GJ, Ishiui Y, Dawn A et al. In vitro and in vivo characterization of a novel liposomal butorphanol formulation for treatment of pruritus. *Acta Derm Venereol* 2008; **88**:327–30.
- 60 Zhang Q, Putheti P, Zhou Q et al. Structure and biological functions of IL-31 and IL-31 receptors. *Cytokine Growth Factor Rev* 2008; **19**:347–56.
- 61 Dillon SR, Sprecher C, Hammond A et al. Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice. *Nat Immunol* 2004; **5**:752–60.
- 62 Sonkoly E, Muller A, Lauerma AI et al. IL-31: a new link between T cells and pruritus in atopic skin inflammation. *J Allergy Clin Immunol* 2006; **117**:411–17.
- 63 Schulz F, Marenholz I, Fölster-Holst R et al. A common haplotype of the IL-31 gene influencing gene expression is associated with nonatopic eczema. *J Allergy Clin Immunol* 2007; **120**:1097–102.
- 64 Tanaka A, Arita K, Lai-Cheong JE et al. New insight into mechanisms of pruritus from molecular studies on familial primary localized cutaneous amyloidosis. *Br J Dermatol* 2009; **161**:1217–24.
- 65 Lin MW, Lee DD, Liu TT et al. Novel IL31RA gene mutation and ancestral OSMR mutant allele in familial primary cutaneous amyloidosis. *Eur J Hum Genet* 2010; **18**:26–32.
- 66 Grimstad O, Sawanobori Y, Vestergaard C et al. Anti-interleukin-31-antibodies ameliorate scratching behaviour in NC/Nga mice: a model of atopic dermatitis. *Exp Dermatol* 2009; **18**:35–43.
- 67 Stander S, Moormann C, Schumacher M et al. Expression of vanilloid receptor subtype 1 in cutaneous sensory nerve fibers, mast cells, and epithelial cells of appendage structures. *Exp Dermatol* 2004; **13**:129–39.
- 68 Bodo E, Kovacs I, Telek A et al. Vanilloid receptor-1 (VR1) is widely expressed on various epithelial and mesenchymal cell types of human skin. *J Invest Dermatol* 2004; **123**:410–13.
- 69 Denda M, Fuziwara S, Inoue K et al. Immunoreactivity of VR1 on epidermal keratinocyte of human skin. *Biochem Biophys Res Commun* 2001; **285**:1250–2.
- 70 Yosipovitch G, Greaves MW, Schmelz M. Itch. *Lancet* 2003; **361**:690–4.
- 71 Stander S, Steinhoff M. Pathophysiology of pruritus in atopic dermatitis: an overview. *Exp Dermatol* 2002; **11**:12–24.
- 72 Imamachi N, Park GH, Lee H et al. TRPV1-expressing primary afferents generate behavioral responses to pruritogens via multiple mechanisms. *Proc Natl Acad Sci USA* 2009; **106**:11330–5.
- 73 Shim WS, Tak MH, Lee MH et al. TRPV1 mediates histamine-induced itching via the activation of phospholipase A2 and 12-lipoxygenase. *J Neurosci* 2007; **27**:2331–7.
- 74 Mohapatra DP, Nau C. Desensitization of capsaicin-activated currents in the vanilloid receptor TRPV1 is decreased by the cyclic AMP-dependent protein kinase pathway. *J Biol Chem* 2003; **278**:50080–90.
- 75 Chuang HH, Prescott ED, Kong H et al. Bradykinin and nerve growth factor release the capsaicin receptor from PtdIns(4,5)P2-mediated inhibition. *Nature* 2001; **411**:957–62.
- 76 Hwang SW, Cho H, Kwak J et al. Direct activation of capsaicin receptors by products of lipoxygenases: endogenous capsaicin-like substances. *Proc Natl Acad Sci USA* 2000; **97**:6155–60.
- 77 Papoiu AD, Yosipovitch G. Topical capsaicin. The fire of a 'hot' medicine is reignited. *Expert Opin Pharmacother* 2010; **11**:1359–71.
- 78 Tarnag DC, Cho YL, Liu HN, Huang TP. Hemodialysis-related pruritus: a double-blind, placebo-controlled, crossover study of capsaicin 0.025% cream. *Nephron* 1996; **72**:617–22.
- 79 Ellis CN, Berberian B, Sulica VI et al. A double-blind evaluation of topical capsaicin in pruritic psoriasis. *J Am Acad Dermatol* 1993; **29**:438–42.
- 80 Lotti T, Teofoli P, Tsampaw D. Treatment of aquagenic pruritus with topical capsaicin cream. *J Am Acad Dermatol*. 1994; **30**:232–5.
- 81 Yosipovitch G, Maibach HI, Rowbotham MC. Effect of EMLA pre-treatment on capsaicin-induced burning and hyperalgesia. *Acta Derm Venereol* 1999; **79**:118–21.
- 82 Noto C, Pappagallo M, Szallasi A. NGX-4010, a high-concentration capsaicin dermal patch for lasting relief of peripheral neuropathic pain. *Curr Opin Investig Drugs* 2009; **10**:702–10.
- 83 Fleischer AB Jr, Boguniewicz M. An approach to pruritus in atopic dermatitis: a critical systematic review of the tacrolimus ointment literature. *J Drugs Dermatol* 2010; **9**:488–98.
- 84 Mettang M, Weisshaar E. Pruritus: control of itch in patients undergoing dialysis. *Skin Therapy Lett* 2010; **15**:1–5.
- 85 Stander S, Schurmeyer-Horst F, Luger TA et al. Treatment of pruritic diseases with topical calcineurin inhibitors. *Ther Clin Risk Manag* 2006; **2**:213–18.
- 86 Pereira U, Boulais N, Lebonvallet N et al. Mechanisms of the sensory effects of tacrolimus on the skin. *Br J Dermatol* 2010; **163**:70–7.
- 87 Xu H, Ramsey IS, Kotecha SA et al. TRPV3 is a calcium-permeable temperature-sensitive cation channel. *Nature* 2002; **418**:181–6.
- 88 Asakawa M, Yoshioka T, Matsutani T et al. Association of a mutation in TRPV3 with defective hair growth in rodents. *J Invest Dermatol* 2006; **126**:2664–72.
- 89 Yoshioka T, Imura K, Asakawa M et al. Impact of the Gly573Ser substitution in TRPV3 on the development of allergic and pruritic dermatitis in mice. *J Invest Dermatol* 2009; **129**:714–22.
- 90 Steinhoff M, Biró T. A TR(I)P to pruritus research: role of TRPV3 in inflammation and itch. *J Invest Dermatol* 2009; **129**:531–5.
- 91 Xu H, Blair NT, Clapham DE. Camphor activates and strongly desensitizes the transient receptor potential vanilloid subtype 1 channel in a vanilloid-independent mechanism. *J Neurosci* 2005; **25**:8924–37.
- 92 Rukwied R, Dvorak M, Watkinson A, McGlone F. Putative role of cannabinoids in experimentally induced itch and inflammation in human skin. In: *Itch: Basic Mechanisms and Therapy* (Yosipovitch G, Greaves MW, Fleischer AB Jr, McGlone F, eds). New York: Marcel Dekker Inc, 2004; 115–30.
- 93 Dvorak M, Watkinson A, McGlone F, Rukwied R. Histamine induced responses are attenuated by a cannabinoid receptor agonist in human skin. *Inflamm Res* 2003; **52**:238–45.
- 94 Darmani NA, Pandya DK. Involvement of other neurotransmitters in behaviors induced by the cannabinoid CB1 receptor antagonist SR 141716A in naive mice. *J Neural Transm* 2000; **107**:931–45.
- 95 Eberlein B, Eicke C, Reinhardt HW, Ring J. Adjuvant treatment of atopic eczema: assessment of an emollient containing N-palmitoylethanolamine (ATOPA study). *J Eur Acad Dermatol Venereol* 2008; **22**:73–82.
- 96 Di Marzo V, Melck D, Orlando P et al. Palmitoylethanolamide inhibits the expression of fatty acid amide hydrolase and enhances anti-proliferative effect of anandamide in human breast cancer cells. *Biochem J* 2001; **358**:249–55.
- 97 Sántha P, Jenes A, Somogyi C, Nagy I. The endogenous cannabinoid anandamide inhibits transient receptor potential vanilloid type 1 receptor-mediated currents in rat cultured primary sensory neurons. *Acta Physiol Hung* 2010; **97**:149–58.
- 98 Schlosburg JE, Boger DL, Cravatt BF, Lichtman AH. Endocannabinoid modulation of scratching response in an acute allergic model: a new prospective neural therapeutic target for pruritus. *J Pharmacol Exp Ther* 2009; **329**:314–23.

- 99 Ahn K, Johnson DS, Fitzgerald LR et al. Novel mechanistic class of fatty acid amide hydrolase inhibitors with remarkable selectivity. *Biochemistry* 2007; **46**:13019–30.
- 100 Clapper JR, Moreno-Sanz G, Russo R et al. Anandamide suppresses pain initiation through a peripheral endocannabinoid mechanism. *Nat Neurosci* 2010; **13**:1265–70.
- 101 Groneberg DA, Serowka F, Peckenschneider N et al. Gene expression and regulation of nerve growth factor in atopic dermatitis mast cells and the human mast cell line-1. *J Neuroimmunol* 2005; **161**:87–92.
- 102 Albers KM, Wright DE, Davis BM. Overexpression of nerve growth factor in epidermis of transgenic mice causes hypertrophy of the peripheral nervous system. *J Neurosci* 1994; **14**:1422–32.
- 103 Verge VM, Richardson PM, Wiesenfeld-Hallin Z, Hokfelt T. Differential influence of nerve growth factor on neuropeptide expression in vivo: a novel role in peptide suppression in adult sensory neurons. *J Neurosci* 1995; **15**:2081–96.
- 104 Dou YC, Hagströmer L, Emtestam L, Johansson O. Increased nerve growth factor and its receptors in atopic dermatitis: an immunohistochemical study. *Arch Dermatol Res* 2006; **298**:31–7.
- 105 Yamaguchi J, Aihara M, Kobayashi Y et al. Quantitative analysis of nerve growth factor (NGF) in the atopic dermatitis and psoriasis horny layer and effect of treatment on NGF in atopic dermatitis. *J Dermatol Sci* 2009; **53**:48–54.
- 106 Johansson O, Liang Y, Emtestam L. Increased nerve growth factor- and tyrosine kinase A-like immunoreactivities in prurigo nodularis skin – an exploration of the cause of neurohyperplasia. *Arch Dermatol Res* 2002; **293**:614–19.
- 107 Choi JC, Yang JH, Chang SE, Choi JH. Pruritus and nerve growth factor in psoriasis. *Korean J Dermatol* 2005; **43**:769–73.
- 108 Kinkelin I, Motzing S, Koltzenburg M, Brocker EB. Increase in NGF content and nerve fiber sprouting in human allergic contact eczema. *Cell Tissue Res* 2000; **302**:31–7.
- 109 Takano N, Sakurai T, Kurachi M. Effects of anti-nerve growth factor antibody on symptoms in the NC/Nga mouse, an atopic dermatitis model. *J Pharmacol Sci* 2005; **99**:277–86.
- 110 Takano N, Sakurai T, Ohashi Y, Kurachi M. Effects of high-affinity nerve growth factor receptor inhibitors on symptoms in the NC/Nga mouse atopic dermatitis model. *Br J Dermatol* 2007; **156**:241–6.
- 111 Sevcik MA, Ghilardi JR, Peters CM et al. Anti-NGF therapy profoundly reduces bone cancer pain and the accompanying increase in markers of peripheral and central sensitization. *Pain* 2005; **115**:128–41.
- 112 Halvorson KG, Kubota K, Sevcik MA et al. A blocking antibody to nerve growth factor attenuates skeletal pain induced by prostate tumor cells growing in bone. *Cancer Res* 2005; **65**:9426–35.
- 113 Jimenez-Andrade JM, Martin CD, Koewler NJ. Nerve growth factor sequestering therapy attenuates non-malignant skeletal pain following fracture. *Pain* 2007; **133**:183–96.
- 114 Cattaneo A. Tanezumab, a recombinant humanized mAb against nerve growth factor for the treatment of acute and chronic pain. *Curr Opin Mol Ther* 2010; **12**:94–106.
- 115 Lane NE, Schnitzer TJ, Birbara CA et al. Tanezumab for the treatment of pain from osteoarthritis of the knee. *N Engl J Med* 2010; **363**:1521–31.
- 116 Clinical Trials. *Tanezumab*. 2010. Available at: <http://www.clinicaltrials.gov/ct2/results?term=tanezumab> (last accessed 5 February 2011).
- 117 Grewe M, Vogelsang K, Ruzicka T et al. Neurotrophin-4 production by human epidermal keratinocytes: increased expression in atopic dermatitis. *J Invest Dermatol* 2000; **114**:1108–12.
- 118 Hon KL, Lam MC, Wong KY et al. Pathophysiology of nocturnal scratching in childhood atopic dermatitis: the role of brain-derived neurotrophic factor and substance P. *Br J Dermatol* 2007; **157**:922–5.
- 119 Scott A. Acetylcholine in normal and diseased skin. *Br J Dermatol* 1962; **74**:317–22.
- 120 Miyamoto T, Nojima H, Kuraishi Y. Intradermal cholinergic agonists induce itch-associated response via M3 muscarinic acetylcholine receptors in mice. *Jpn J Pharmacol* 2002; **88**:351–4.
- 121 Heyer G, Vogelsang M, Hornstein OP. Acetylcholine is an inducer of itching in patients with atopic eczema. *J Dermatol* 1997; **24**:621–5.
- 122 Vogelsang M, Heyer G, Hornstein OP. Acetylcholine induces different cutaneous sensations in atopic and non-atopic subjects. *Acta Derm Venereol* 1995; **75**:434–6.
- 123 Gazerani P, Pedersen NS, Drewes AM, Arendt-Nielsen L. Botulinum toxin type A reduces histamine-induced itch and vasomotor responses in human skin. *Br J Dermatol* 2009; **161**:737–45.
- 124 Tugnoli V, Capone JG, Eleopra R et al. Botulinum toxin type A reduces capsaicin-evoked pain and neurogenic vasodilatation in human skin. *Pain* 2007; **130**:76–83.
- 125 Gazerani P, Pedersen NS, Staahl C et al. Subcutaneous botulinum toxin type A reduces capsaicin-induced trigeminal pain and vasomotor reactions in human skin. *Pain* 2009; **141**:60–9.
- 126 Kramer HH, Angerer C, Erbguth F et al. Botulinum toxin A reduces neurogenic flare but has almost no effect on pain and hyperalgesia in human skin. *J Neurol* 2003; **250**:188–93.
- 127 Heckmann M, Heyer G, Brunner B, Plewig G. Botulinum toxin type A injection in the treatment of lichen simplex: an open pilot study. *J Am Acad Dermatol* 2002; **46**:617–19.
- 128 Weinfeld PK. Successful treatment of notalgia paresthetica with botulinum toxin type A. *Arch Dermatol* 2007; **143**:980–2.
- 129 Salardini A, Richardson D, Jabbari B. Relief of intractable pruritus after administration of botulinum toxin A (Botox): a case report. *Clin Neuropharmacol* 2008; **31**:303–6.
- 130 Wallengren J, Bartosik J. Botulinum toxin type A for neuropathic itch. *Br J Dermatol* 2010; **163**:424–6.
- 131 Liu T, Xu ZZ, Park CK et al. Toll-like receptor 7 mediates pruritus. *Nat Neurosci* 2010; **13**:1460–2.
- 132 Sun YG, Chen ZF. A gastrin-releasing peptide receptor mediates the itch sensation in the spinal cord. *Nature* 2007; **448**:700–3.
- 133 Sun YG, Zhao ZQ, Meng XL et al. Cellular basis of itch sensation. *Science* 2009; **325**:1531–4.
- 134 Liu Q, Tang Z, Surdenikova L et al. Sensory neuron-specific GPCR Mrgprs are itch receptors mediating chloroquine-induced pruritus. *Cell* 2009; **139**:1353–65.
- 135 Bandell M, Patapoutian A. Itching for insight. *Cell* 2009; **139**:1224–6.
- 136 Amatya B, Nordlind K, Wahlgren CF. Responses to intradermal injections of substance P in psoriasis patients with pruritus. *Skin Pharmacol Physiol* 2010; **23**:133–8.
- 137 Weidner C, Klede M, Rukwied R et al. Acute effects of substance P and calcitonin gene-related peptide in human skin – a microdialysis study. *J Invest Dermatol* 2000; **115**:1015–20.
- 138 Almeida TA, Rojo J, Nieto PM et al. Tachykinins and tachykinin receptors: structure and activity relationships. *Curr Med Chem* 2004; **11**:2045–81.
- 139 Carstens EE, Carstens MI, Simons CT, Jinks SL. Dorsal horn neurons expressing NK-1 receptors mediate scratching in rats. *Neuroreport* 2010; **21**:303–8.
- 140 Dando TM, Perry C. Aprepitant: a review of its use in the prevention of chemotherapy-induced nausea and vomiting. *Drugs* 2004; **64**:777–94.

- 141 Duval A, Dubertret L. Aprepitant as an antipruritic agent? *N Engl J Med* 2009; **361**:1415–16.
- 142 Booken N, Heck M, Nicolay J et al. Oral aprepitant is highly efficient in the therapy of refractory pruritus in erythrodermic cutaneous T-cell lymphoma. *Br J Dermatol* 2010; **164**:665–7.
- 143 Vincenzi B, Fratto ME, Santini D, Tonini G. Aprepitant against pruritus in patients with solid tumours. *Support Care Cancer* 2010; **18**:1229–30.
- 144 Vincenzi B, Tonini G, Santini D. Aprepitant for erlotinib-induced pruritus. *N Engl J Med* 2010; **363**:397–8.
- 145 Ständer S, Siepmann D, Herrgott I et al. Targeting the neurokinin receptor 1 with aprepitant: a novel antipruritic strategy. *PLoS ONE* 2010; **5**:e10968.
- 146 Kremer AE, Martens JJ, Kulik W et al. Lysophosphatidic acid is a potential mediator of cholestatic pruritus. *Gastroenterology* 2010; **139**:1008–18e1.
- 147 Schmelz M. Itch and pain. *Neurosci Biobehav Rev* 2010; **34**:171–6.
- 148 Yosipovitch G, Carstens E, McGlone F. Chronic itch and chronic pain: analogous mechanisms. *Pain* 2007; **131**:4–7.
- 149 Tracey I. Neuroimaging of pain mechanisms. *Curr Opin Support Palliat Care* 2007; **1**:109–16.
- 150 Ishiuiji Y, Coghill RC, Patel TS et al. Distinct patterns of brain activity evoked by histamine-induced itch reveal an association with itch intensity and disease severity in atopic dermatitis. *Br J Dermatol* 2009; **161**:1072–80.
- 151 Mochizuki H, Inui K, Tanabe HC et al. Time course of activity in itch-related brain regions: a combined MEG-fMRI study. *J Neurophysiol* 2009; **102**:2657–66.
- 152 Yosipovitch G, Ishiuiji Y, Patel TS et al. The brain processing of scratching. *J Invest Dermatol* 2008; **128**:1806–11.
- 153 Farr SA, Uezu K, Creonte TA et al. Modulation of memory processing in the cingulate cortex of mice. *Pharmacol Biochem Behav* 2000; **65**:363–8.
- 154 Bush G, Luu P, Posner MI. Cognitive and emotional influences in anterior cingulate cortex. *Trends Cogn Sci* 2000; **4**:215–22.
- 155 Hundley JL, Yosipovitch G. Mirtazapine for reducing nocturnal itch in patients with chronic pruritus: a pilot study. *J Am Acad Dermatol* 2004; **50**:889–91.
- 156 Demierre MF, Taverna J. Mirtazapine and gabapentin for reducing pruritus in cutaneous T-cell lymphoma. *J Am Acad Dermatol* 2006; **55**:543–4.
- 157 Davis MP, Frandsen JL, Walsh D et al. Mirtazapine for pruritus. *J Pain Symptom Manage* 2003; **25**:288–91.
- 158 Clinical Trials. ORG 50081. 2010. Available at: <http://clinicaltrials.gov/ct2/results?term=ORG+50081> (last accessed 5 February 2011).
- 159 Becker JR. *Future Treatments for Depression, Anxiety, Sleep Disorders, Psychosis, and ADHD*. 2009. Available at: <http://www.neurotransmitter.net/newdrugs.html> (last accessed 5 February 2011).
- 160 Lee YC, Chen PP. A review of SSRIs and SNRIs in neuropathic pain. *Expert Opin Pharmacother* 2010; **11**:2813–25.
- 161 Brocco M, Dekeyne A, Mannoury la Cour C et al. Cellular and behavioural profile of the novel, selective neurokinin1 receptor antagonist, vestipitant: a comparison to other agents. *Eur Neuropsychopharmacol* 2008; **18**:729–50.
- 162 GlaxoSmithKline. *A Combination Therapy in Patients with Social Anxiety Disorder*. 2008. Available at: <http://www.clinicaltrials.gov/ct2/results?term=vestipitant&rank=4> (last accessed 5 February 2011).
- 163 Varty GB, Cohen-Williams ME, Hunter JC. The antidepressant-like effects of neurokinin NK1 receptor antagonists in a gerbil tail suspension test. *Behav Pharmacol* 2003; **14**:87–95.
- 164 Wallace-Boone TL, Newton AE, Wright RN et al. Behavioral and pharmacological validation of the gerbil forced-swim test: effects of neurokinin-1 receptor antagonists. *Neuropsychopharmacology* 2008; **33**:1919–28.
- 165 Varty GB, Cohen-Williams ME, Morgan CA et al. The gerbil elevated plus-maze II: anxiolytic-like effects of selective neurokinin NK1 receptor antagonists. *Neuropsychopharmacology* 2002; **27**:371–9.
- 166 Keller M, Montgomery S, Ball W et al. Lack of efficacy of the substance P (neurokinin1 receptor) antagonist aprepitant in the treatment of major depressive disorder. *Biol Psychiatry* 2006; **59**:216–23.
- 167 Gunal AI, Ozalp G, Yoldas TK et al. Gabapentin therapy for pruritus in haemodialysis patients: a randomized, placebo-controlled, double-blind trial. *Nephrol Dial Transplant* 2004; **19**:3137–9.
- 168 Razeghi E, Eskandari D, Ganji MR et al. Gabapentin and uremic pruritus in hemodialysis patients. *Ren Fail* 2009; **31**:85–90.
- 169 Bergasa NV, McGee M, Ginsburg IH, Engler D. Gabapentin in patients with the pruritus of cholestasis: a double-blind, randomized, placebo-controlled trial. *Hepatology* 2006; **44**:1317–23.
- 170 Markell MS. Potential benefits of complementary medicine modalities in patients with chronic kidney disease. *Adv Chronic Kidney Dis* 2005; **12**:292–9.
- 171 Rucklidge JJ, Saunders D. The efficacy of hypnosis in the treatment of pruritus in people with HIV/AIDS: a time-series analysis. *Int J Clin Exp Hypn* 2002; **50**:149–69.
- 172 Shenefelt PD. Hypnosis in dermatology. *Arch Dermatol* 2000; **136**:393–9.
- 173 Shenefelt PD. Biofeedback, cognitive-behavioral methods, and hypnosis in dermatology: is it all in your mind? *Dermatol Ther* 2003; **16**:114–22.
- 174 Chida Y, Steptoe A, Hirakawa N et al. The effects of psychological intervention on atopic dermatitis. A systematic review and meta-analysis. *Int Arch Allergy Immunol* 2007; **144**:1–9.